Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Alfama Inc.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions Database, providing comprehensive transaction coverage from 1991 to the present.
Two companies active in carbon monoxide research, Alfama and hemoCORM, have merged to create a leader in the field of carbon monoxide-releasing molecules (CORM). Researchers at both companies have been developing compounds that can release carbon monoxide in minute amounts after oral or injectable administration, and have shown promise in a range of acute and chronic inflammatory diseases.
The founders of European start-ups hemoCORM Ltd. and Alfama are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.
The founders of European start-ups Alfama and hemoCORM Ltd. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.